ZYBT Stock Analysis: Buy, Sell, or Hold?
ZYBT - Zhengye Biotechnology Holding Limited Ordinary Shares
$1.55
-0.04 (-2.52%)
âŧ
5d:
-4.91%
30d:
+0.0%
90d:
+72.22%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Jul 28, 2026
0d
Get Alerted When ZYBT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ZYBT is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ZYBT is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: ZYBT is currently trading at $1.55, which is considered slightly low relative to its 30-day fair value range of $1.53 to $1.94.
Technical Outlook: Technically, ZYBT is showing sideways momentum. The price is currently testing key support at $1.55. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ZYBT scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ZYBT is showing sideways momentum. The price is currently testing key support at $1.55. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ZYBT scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.53 -
$1.94
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (35/100)
- BULLISH: High volume confirmation
- WARNING: Composite score 45/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.53 -
$1.94
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$1.55
Resistance Level
$1.81
Current Trend
Sideways
Technical data as of
Sep 11, 2026
Fundamental Context
Revenue Growth (YoY)
-40.9%
Earnings Growth (YoY)
-79.6%
Profit Margin
-60.0%
Share & Embed Analysis
Last updated: September 13, 2026 9:50 PM ET
Data refreshes hourly during market hours. Next update: 10:50 PM
Data refreshes hourly during market hours. Next update: 10:50 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZYBT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$211 | 60 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 70 BUY |
|
INDV
Indivior PLC Ordinary ShâĻ |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 46 HOLD |
|
UTHR
United Therapeutics CorpâĻ |
STRONG BUY
15 analysts |
$664 | 47 HOLD |
